1. Home
  2. ICUI vs PRCT Comparison

ICUI vs PRCT Comparison

Compare ICUI & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICUI
  • PRCT
  • Stock Information
  • Founded
  • ICUI 1984
  • PRCT 2009
  • Country
  • ICUI United States
  • PRCT United States
  • Employees
  • ICUI N/A
  • PRCT N/A
  • Industry
  • ICUI Medical/Dental Instruments
  • PRCT Medical Specialities
  • Sector
  • ICUI Health Care
  • PRCT Health Care
  • Exchange
  • ICUI Nasdaq
  • PRCT Nasdaq
  • Market Cap
  • ICUI 3.4B
  • PRCT 3.2B
  • IPO Year
  • ICUI 1992
  • PRCT 2021
  • Fundamental
  • Price
  • ICUI $134.86
  • PRCT $58.00
  • Analyst Decision
  • ICUI Strong Buy
  • PRCT Strong Buy
  • Analyst Count
  • ICUI 5
  • PRCT 7
  • Target Price
  • ICUI $196.75
  • PRCT $90.00
  • AVG Volume (30 Days)
  • ICUI 272.7K
  • PRCT 814.8K
  • Earning Date
  • ICUI 05-08-2025
  • PRCT 04-24-2025
  • Dividend Yield
  • ICUI N/A
  • PRCT N/A
  • EPS Growth
  • ICUI N/A
  • PRCT N/A
  • EPS
  • ICUI N/A
  • PRCT N/A
  • Revenue
  • ICUI $2,420,093,000.00
  • PRCT $249,121,000.00
  • Revenue This Year
  • ICUI N/A
  • PRCT $47.40
  • Revenue Next Year
  • ICUI N/A
  • PRCT $31.81
  • P/E Ratio
  • ICUI N/A
  • PRCT N/A
  • Revenue Growth
  • ICUI 7.22
  • PRCT 59.36
  • 52 Week Low
  • ICUI $101.44
  • PRCT $47.04
  • 52 Week High
  • ICUI $196.26
  • PRCT $103.81
  • Technical
  • Relative Strength Index (RSI)
  • ICUI 48.47
  • PRCT 54.16
  • Support Level
  • ICUI $127.91
  • PRCT $55.18
  • Resistance Level
  • ICUI $135.62
  • PRCT $59.06
  • Average True Range (ATR)
  • ICUI 4.35
  • PRCT 2.64
  • MACD
  • ICUI -0.26
  • PRCT 0.16
  • Stochastic Oscillator
  • ICUI 33.77
  • PRCT 78.08

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

About PRCT PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.

Share on Social Networks: